Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cladribine for multiple sclerosis: review and current status.

Jack C Sipe1

  • 1Department of Molecular and Experimental Medicine, The Scripps Research Institute, and Scripps Clinic, 10550 North Torrey Pines Road (MEM-215), LaJolla, CA 92037 USA. jcsipe@scripps.edu

Expert Review of Neurotherapeutics
|November 9, 2005
PubMed
Summary

Cladribine, a nucleoside analog, shows promise for treating lymphoid cancers and autoimmune disorders like multiple sclerosis. A new oral formulation is being studied in a Phase III trial for relapsing multiple sclerosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population sequencing of two endocannabinoid metabolic genes identifies rare and common regulatory variants associated with extreme obesity and metabolite level.

Genome biology·2010
Same author

Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.

Expert review of neurotherapeutics·2010
Same author

Biomarkers of endocannabinoid system activation in severe obesity.

PloS one·2010
Same author

Cladribine tablets' potential in multiple: sclerosis treatment.

The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses·2008
Same author

The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics·2007
Same author

The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction.

Human genetics·2006

Area of Science:

  • Pharmacology
  • Immunology
  • Neurology

Background:

  • Cladribine, an adenosine deaminase-resistant nucleoside analog, was developed for lymphoid neoplasms and autoimmune disorders.
  • Previous studies indicated cladribine's effectiveness and safety in treating hairy-cell leukemia and other lymphoid malignancies.
  • Cladribine demonstrated efficacy, tolerability, and acceptable toxicity in multiple sclerosis (MS) patients.

Purpose of the Study:

  • To review the clinical studies and current status of cladribine for multiple sclerosis treatment.
  • To report on the initiation of a Phase III study for oral cladribine (Mylinax) in relapsing-remitting multiple sclerosis.

Main Methods:

  • Review of previous clinical trials and existing data on cladribine in autoimmune disorders, particularly MS.

Related Experiment Videos

  • Announcement of a planned Phase III, large, multicenter, randomized controlled clinical trial for oral cladribine in relapsing forms of MS.

    • Main Results:

    • Cladribine has shown significant effectiveness and safety in treating hairy-cell leukemia and other lymphoid malignancies.
    • Evidence suggests cladribine's efficacy, tolerability, and acceptable side effect profile in multiple sclerosis.
    • A new oral formulation (Mylinax) is being investigated for relapsing MS.

    Conclusions:

    • Cladribine is a viable therapeutic option for certain lymphoid neoplasms and autoimmune disorders.
    • Further investigation via a Phase III trial is warranted for oral cladribine in relapsing multiple sclerosis.